Every analysis published by Psychiatry Evidence Base is an independent critical reading of a scientific publication, scored on the PEB grid. The English versions are listed below, most recent first.
PEB is a French-language journal. Each analysis is written in French, then published in English alongside it. Where no English version exists yet, the French one is the only one, and the French site carries it.
100 analyses
▤ Dossier◆◆◆◆◆2B
Joint prediction of psychosis and bipolar disorder risk from the clinical record: what is the South London model worth?
The Lancet Psychiatry · Arribas et al.
Read the analysis→
◆ Collection◆◆◆◆◆1B
Augmenting an antidepressant with an antipsychotic after four weeks of inadequate response: what does the perospirone trial show?
eClinicalMedicine · Liu et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Which exercise, at what dose, for better sleep? What a network meta-analysis of 58 trials shows
Frontiers in Psychology · Li et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Esketamine in treatment-resistant depression: what is known about its effects on work and social life, beyond symptoms?
Journal of Psychiatric Research · Ji et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Repurposed antihypertensives for negative symptoms in schizophrenia: what the meta-analysis can and cannot say
Psychiatry and Clinical Neurosciences · Carnaval et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
Atypical antipsychotics for autistic children: reading a network ranking against the clinical threshold
Cochrane Database of Systematic Reviews · Meza et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Pramipexole augmentation in treatment-resistant depression: what the PAX-D economic evaluation shows
The Lancet Regional Health – Europe · Łaszewska et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Circulating lipids and Alzheimer’s disease biomarkers: what does the ADNI cohort show?
Molecular Psychiatry · Kim et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Cognitive behavioural therapy alone for stimulant use disorders: reading an odds ratio of 2.88 alongside its certainty
Frontiers in Psychiatry · Kim et al.
Read the analysis→
◆ Collection◆◆◆◆◆2A
Cardiorespiratory fitness and later risk of mental disorders: a steady association, an unclear direction
Nature Mental Health · Díaz-Goñi et al.
Read the analysis→
◆ Collection◆◆◆◆◆2A
Bipolar disorder with comorbid obsessive-compulsive disorder: a more severe clinical profile?
European Psychiatry · De Prisco et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
Esketamine in treatment-resistant depression: do adverse effects depend on the dose?
Frontiers in Pharmacology · Qu Y et al.
Read the analysis→
◆ Collection◆◆◆◆◆1B
Varenicline and bupropion for alcohol use disorder: the trial announces a combination, it demonstrates a monotherapy
The Lancet Regional Health – Europe · Söderpalm et al.
Read the analysis→
◆ Collection◆◆◆◆◆2A
Anxiety disorders, mortality, and suicide: what does a synthesis of 165 studies show?
World Psychiatry · Wagner et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
In autism spectrum disorder, does the right non-drug intervention depend on the symptom?
Frontiers in Psychiatry · Ding et al.
Read the analysis→
◆ Collection◆◆◆◆◆3B
Racemic ketamine or intranasal esketamine: similar score drops, different remission rates
Journal of Affective Disorders · Sarlon et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
Lamotrigine and depression: real prevention in bipolar disorder, a marginal acute effect, no evidence in unipolar depression
Pharmaceuticals · Arnone et al.
Read the analysis→
◆ Collection◆◆◆◆◆1B
Esketamine without an oral antidepressant: what does a placebo-controlled trial show?
JAMA Psychiatry · Janik et al.
Read the analysis→
◆ Collection◆◆◆◆◆2B
Antipsychotic nonadherence and mortality in schizophrenia: does the association hold up to scrutiny?
European Neuropsychopharmacology · Correll et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
After a successful course of ECT, should maintenance sessions continue alongside medication?
Psychological Medicine · Jelovac et al.
Read the analysis→
◆ Collection◆◆◆◆◆n.r.
Intermittent theta burst stimulation for depressed adolescents: what does the evidence actually show?
Journal of Affective Disorders · Deng et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
GLP-1 receptor agonists and alcohol: what holds up once trials and cohorts are kept apart
Addiction Science & Clinical Practice · Sinha and Ghosal
Read the analysis→
◆ Collection◆◆◆◆◆n.r.
Early-onset psychosis: what thirty meta-analyses say about prognosis and antipsychotic choice
Journal of the American Academy of Child and Adolescent Psychiatry · Salazar de Pablo G et al.
Read the analysis→
◆ Collection◆◆◆◆◆1B
Pramipexole for anhedonic depression: what this trial demonstrates, and what it does not
Nature Medicine · Ventorp et al.
Read the analysis→
▬ Publication◆◆◆◆◆4
Psilocybin for PTSD: what a 22-patient open trial actually shows, and what it does not
Journal of Psychopharmacology · McGowan et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Brexpiprazole add-on for minimal and partial antidepressant responders: significant, but by a narrow margin
International Journal of Neuropsychopharmacology · Kapadia et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
rTMS or esketamine for treatment-resistant depression: a target trial emulation that still can’t settle the choice
Journal of Affective Disorders · Chen et al.
Read the analysis→
▬ Publication◆◆◆◆◆1B
Before the gaokao: a writing intervention that missed its own primary outcome
BMC Medicine · Luo et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Psilocybin and major depression: what remains at twelve months once the blind breaks down
JAMA Network Open · Yngwe et al.
Read the analysis→
▬ Publication◆◆◆◆◆4
In treatment-resistant OCD with comorbid depression, does intranasal esketamine work faster on mood than on obsessions?
BMC Psychiatry · López-Rodríguez et al.
Read the analysis→
▬ Publication◆◆◆◆◆3B
In Schizophrenia, Two Patients in Three Show Sarcopenia in a Turkish Sample
Schizophrenia Research · Şişman & Önen
Read the analysis→
▬ Publication◆◆◆◆◆2C
Summer heat and youth suicide: what can a US county-level ecological study actually tell us?
American Journal of Psychiatry · Jayaraman et al.
Read the analysis→
▬ Publication◆◆◆◆◆4
Group EMDR for forced migrants: what can an uncontrolled pre-post series actually show?
European Journal of Psychotraumatology · Chauliac et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Pramipexole in resistant bipolar depression: a trial closed at thirteen percent of target, with a signal on hypomanic symptoms
Journal of Psychopharmacology · McAllister-Williams et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Aerobic or mind-body exercise for substance use disorders: what does the ranking actually show?
Frontiers in Psychiatry · Liu et al.
Read the analysis→
▬ Publication◆◆◆◆◆n.r.
Does bipolar disorder change the symptom profile of obsessive-compulsive disorder?
European Neuropsychopharmacology · De Prisco et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Can mismatch negativity predict response to iTBS in depression?
Journal of Affective Disorders · Anderson et al.
Read the analysis→
▬ Publication◆◆◆◆◆3B
Can we predict, before the first session, whose anhedonia will respond to rTMS?
Translational Psychiatry · Abram et al.
Read the analysis→
▬ Publication◆◆◆◆◆3A
After a successful course of ECT, which relapse-prevention strategies actually hold up?
BJPsych Open · Rovers et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Donepezil, galantamine, rivastigmine: what does a comparison of effect sizes actually show?
Advances in Clinical and Experimental Medicine · Gao et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
High-frequency rTMS for negative symptoms in schizophrenia: a small effect, and two sets of numbers
PLOS One · Wang et al.
Read the analysis→
▬ Publication◆◆◆◆◆3B
An apparent 90% drop in dementia treatment after antiviral use: what should we make of an effect this large?
BMJ Open · Alghamdi et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
In ADHD, does the type of physical activity change the cognitive benefit?
Frontiers in Psychiatry · Chen et al.
Read the analysis→
▬ Publication◆◆◆◆◆1B
Brexpiprazole for adolescent schizophrenia: what is a statistically positive PANSS result actually worth?
The Lancet Psychiatry · Ward et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
An azapirone added to an SSRI in vascular depression of the elderly: what does twelve weeks buy?
Journal of Affective Disorders · Zeng et al.
Read the analysis→
▬ Publication◆◆◆◆◆1B
Does an AI clinical decision support tool reduce treatment failures in primary care? A Kenyan cluster-randomized trial finds no difference
Nature Medicine · Agweyu et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Ketamine and suicidal ideation: does treatment resistance change the picture?
International Journal of Neuropsychopharmacology · Liu et al.
Read the analysis→
▬ Publication◆◆◆◆◆1B
Ketogenic diet for treatment-resistant depression: a result at the edge of significance, short of the trial’s own threshold
JAMA Psychiatry · Gao et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
EMDR and substance use disorders: how solid is the signal on craving?
Frontiers in Psychiatry · Seok et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Neurodevelopmental disorders: does the type of physical activity matter more than the amount?
International Journal of Behavioral Nutrition and Physical Activity · Tao R et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Quetiapine or haloperidol for delirium: are 215 patients enough to choose?
Asian Journal of Psychiatry · Zainab et al.
Read the analysis→
▬ Publication◆◆◆◆◆n.r.
Does the same disorder shape the same cortex at fifteen and at forty?
Translational Psychiatry · Cui et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Negative symptoms of schizophrenia: are 451 trials measuring the right symptom?
Molecular Psychiatry · Damiani et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Cannabis legalization in Canada: did use rise more among people with a mental health condition?
The Lancet Regional Health – Americas · Rundle et al.
Read the analysis→
◆ Collection◆◆◆◆◆3A
Parent and child sleep are correlated: what can we conclude, and what can’t we?
Sleep Medicine Reviews · Dai et al.
Read the analysis→
◆ Collection◆◆◆◆◆2B
Anorexia nervosa: a measurable gastric interoception deficit, an unproven prognosis
JAMA Psychiatry · Verdonk et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
Cannabidiol, THC, and the combination: what do the 54 available randomised trials in mental health and addiction actually show?
The Lancet Psychiatry · Wilson et al.
Read the analysis→
◆ Collection◆◆◆◆◆2A
ADHD stimulants in bipolar disorder: does the fear of a manic switch survive 939 hospitalisations for mania?
BMJ Mental Health · Ermis et al.
Read the analysis→
▬ Publication◆◆◆◆◆3A
Fear disorders and generalised anxiety disorder: how far does the genetic background overlap?
Molecular Psychiatry · ter Kuile et al.
Read the analysis→
▬ Publication◆◆◆◆◆2B
Transcranial stimulation in opioid use disorder: does hitting a brain target mean treating the disorder?
Molecular Psychiatry · Soleimani et al.
Read the analysis→
▬ Publication◆◆◆◆◆1A
Auditory hallucinations: what does a targeted psychotherapy actually change?
JAMA Psychiatry · Fässler et al.
Read the analysis→
◆ Collection◆◆◆◆◆2B
Contingency Management and Mortality: What a Veteran Cohort Can and Cannot Prove
The American Journal of Psychiatry · Coughlin et al.
Read the analysis→
◆ Collection◆◆◆◆◆1B
Buprenorphine After Ketamine: Can It Extend the Antisuicidal Effect?
American Journal of Psychiatry · Tucciarone et al.
Read the analysis→
◆ Collection◆◆◆◆◆2B
Lithium or Quetiapine for Augmentation: The First Twelve-Month Head-to-Head Trial
Health Technology Assessment · Kerr-Gaffney et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
Qigong, Tai Chi, Yoga: What Do Mind-Body Exercises Actually Do for Anxiety and Depression?
PeerJ · Ye et al.
Read the analysis→
◆ Collection◆◆◆◆◆1A
Exercise in Bipolar Disorder: Which Symptoms Respond, and How Confident Are We?
Frontiers in Psychiatry · Li et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1B
Magnetic seizure therapy versus ultra-brief ECT: non-inferiority at the edge of its margin
The Lancet Psychiatry · Blumberger et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Stopping cholinesterase inhibitors in Alzheimer’s disease: what do withdrawal trials show?
Cochrane Database of Systematic Reviews · Parsons et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Ketamine versus midazolam in acute suicidality: what is left against an active comparator?
Brain and Behavior · Shah et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1B
MM120 lysergide in generalised anxiety disorder: what is a signal worth when blinding fails?
JAMA · Robison et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Donepezil and reimbursement: what a Cochrane review can tell a family, and what it cannot
Cochrane Database of Systematic Reviews · Birks et al.
Read the analysis→
▤ Dossier◆◆◆◆◆n.r.
Psychiatric guidelines: 11.6% rated high level of evidence. Should we distrust them for that?
BMJ Mental Health · Rømer et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Resistant schizophrenia: what is a minus 1.53 effect size for duloxetine plus clozapine worth?
eClinicalMedicine · Samara M et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Manic switch on antidepressants in bipolar depression: what can a network meta-analysis settle?
eClinicalMedicine · Oliva et al.
Read the analysis→
▤ Dossier◆◆◆◆◆2B
Antipsychotic polytherapy: does combining two drugs really reduce psychiatric readmission?
Comprehensive Psychiatry · Llorca et al.
Read the analysis→
▤ Dossier◆◆◆◆◆n.r.
PTSD and complex PTSD: what do 54 systematic reviews say about treatment?
British Medical Bulletin · Billings et Nicholls
Read the analysis→
★ Premium◆◆◆◆◆1B
Brexpiprazole plus sertraline in PTSD: fixed-dose phase 3 trial does no better than sertraline
Journal of Clinical Psychopharmacology · Davis et al.
Read the analysis→
★ Premium◆◆◆◆◆2B
Intranasal esketamine or rTMS for treatment-resistant depression: a reconstructed comparison
eClinicalMedicine · Kaster TS et al.
Read the analysis→
★ Premium◆◆◆◆◆2B
ADHD medication in children and adolescents: who stops, and when?
BMJ Mental Health · Garcia-Argibay M et al.
Read the analysis→
★ Premium◆◆◆◆◆n.r.
Suicidal behaviour: what does a multivariate GWAS of more than 1.7 million people really show?
medRxiv (préimpression) · He et al.
Read the analysis→
★ Premium◆◆◆◆◆2B
Lithium, valproate, antipsychotics: which is linked to lower suicide risk in bipolar disorder?
Journal of Affective Disorders · Park et al.
Read the analysis→
★ Premium◆◆◆◆◆2B
Amyloid-positive mild cognitive impairment: does the result tell you when dementia will follow?
Molecular Psychiatry · Delaby et al.
Read the analysis→
★ Premium◆◆◆◆◆1A
Psilocybin trials for depression: control groups improve less. What should we conclude?
JAMA Network Open · Hieronymus F et al.
Read the analysis→
★ Premium◆◆◆◆◆n.r.
Once-daily or twice-daily lithium: what does brain MRI show at 12 hours?
The Lancet Psychiatry · Ritter et al.
Read the analysis→
★ Premium◆◆◆◆◆1A
Treatment-resistant depression: what is a network meta-analysis ranking of treatments worth?
Neuropsychopharmacology · Saelens et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1B
Psilocybin in treatment-resistant depression: the EPIsoDE trial misses its primary outcome
JAMA Psychiatry · Mertens et al.
Read the analysis→
▤ Dossier◆◆◆◆◆2B
Does methylphenidate raise the risk of psychotic disorder in young people with ADHD?
JAMA Psychiatry · Healy et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1B
Anxiety screening in primary schools: parents see a benefit, children report none
The Lancet Psychiatry · Reardon et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1B
Online parent-led CBT to prevent child anxiety: what does a trial in 95 English schools show?
Journal of Child Psychology and Psychiatry · Reardon et al.
Read the analysis→
▤ Dossier◆◆◆◆◆3B
Schizophrenia: is synaptic density loss on PET independent of the atrophy seen on MRI?
Molecular Psychiatry · Chopra et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1A
Lithium and suicidality: what can fifteen randomised trials show when events are this rare?
Journal of Affective Disorders · Wang JX et al.
Read the analysis→
▤ Dossier◆◆◆◆◆1B
Virtual reality cognitive remediation: a large effect on cognition, and on daily life?
The Lancet Digital Health · Jespersen et al.
Read the analysis→
▤ Dossier◆◆◆◆◆2B
Plasma proteomic clocks of cell-type ageing: does astrocyte age predict Alzheimer’s disease?
Nature Medicine · Ding et al.
Read the analysis→
▤ Dossier◆◆◆◆◆2A
GLP-1 receptor agonists and psychiatric symptoms: what a systematic review can and cannot show
Brain and Behavior · Meshkat et al.
Read the analysis→
▤ Dossier◆◆◆◆◆2B
Do GLP-1 receptor agonists change the risk of depression in older adults with diabetes?
Annals of Internal Medicine · Tang et al.
Read the analysis→
★ Premium◆◆◆◆◆1A
Adult ADHD: do the treatments hold up when the patient does the rating?
The Lancet Psychiatry · Ostinelli et al.
Read the analysis→
★ Premium◆◆◆◆◆1A
Complex PTSD prevalence: what can be concluded from 167 studies?
Psychiatry Research · Huynh PA et al.
Read the analysis→
★ Premium◆◆◆◆◆1A
Neuromodulation for depression: what does a ranking of fourteen protocols prove?
Psychiatry and Clinical Neurosciences · Wang et al.
Read the analysis→
★ Premium◆◆◆◆◆2A
Diabetes and mental disorders: who gets monitored, who gets treated?
The Lancet Psychiatry · Wagner et al.
Read the analysis→
★ Premium◆◆◆◆◆n.r.
Clozapine in treatment-resistant schizophrenia: no proven symptomatic superiority at 6-8 weeks
The Lancet Psychiatry · Schneider-Thoma et al.
Read the analysis→